Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Matthew Kaczynski"'
Autor:
Bei Wang, Jacquelynn Golubov, Erin M. Oswald, Patrick Poon, Qiaozhi Wei, Clarissa Lett, Fadi Shehadeh, Matthew Kaczynski, Lewis Oscar Felix, Biswajit Mishra, Evangelia K. Mylona, Matthew F. Wipperman, Erica Chio, Sara C. Hamon, Andrea T. Hooper, Selin Somersan-Karakaya, Bret J. Musser, Christopher D. Petro, Jennifer D. Hamilton, Matthew A. Sleeman, George D. Kalliolias, Eleftherios Mylonakis, Dimitris Skokos
Publikováno v:
EBioMedicine, Vol 108, Iss , Pp 105334- (2024)
Summary: Background: Passive administration of SARS-CoV-2 neutralizing monoclonal antibodies (mAbs), such as CAS + IMD (Casirivimab + Imdevimab) antibody cocktail demonstrated beneficial effects on clinical outcomes in hospitalized patients with COVI
Externí odkaz:
https://doaj.org/article/2b0af8e604764c0bbe87f262c39423c8
Autor:
Markos Kalligeros, Fadi Shehadeh, Evangelia K. Mylona, Matthew Kaczynski, Saisanjana Kalagara, Eleftheria Atalla, Maria Tsikala Vafea, Eleftherios Mylonakis
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 6, Iss 4, p 175 (2021)
Vaccination remains the most effective way to prevent COVID-19. The aim of the present study was to assess the incidence of COVID-19 hospitalizations after vaccination, as well as the effect of prior vaccination on hospitalization outcomes among pati
Externí odkaz:
https://doaj.org/article/365468c7f7b4469ca8fa1969afc91c73
Autor:
Fadi Shehadeh, Gregorio Benitez, Evangelia K Mylona, Quynh-Lam Tran, Maria Tsikala-Vafea, Eleftheria Atalla, Matthew Kaczynski, Eleftherios Mylonakis
Publikováno v:
The Journal of Infectious Diseases. 227:226-235
Background Thymosin-α-1 (Tα1) may be a treatment option for coronavirus disease 2019 (COVID-19), but efficacy and safety data remain limited. Methods Prospective, open-label, randomized trial assessing preliminary efficacy and safety of thymalfasin
Autor:
Matthew Kaczynski, Gregorio Benitez, Evangelia K Mylona, Quynh-Lam Tran, Eleftheria Atalla, Maria Tsikala-Vafea, Saisanjana Kalagara, Fadi Shehadeh, Eleftherios Mylonakis
Publikováno v:
Open Forum Infectious Diseases. 10
Background Clinical trials for coronavirus disease 2019 (COVID-19) have struggled to achieve diverse patient enrollment, despite underrepresented groups bearing the largest burden of the disease and, presumably, being most in need of the treatments u
Autor:
Clare Nugent, Yasin Abul, Elizabeth White, Fadi Shehadeh, Matthew Kaczynski, Lewis Oscar Felix, Narchonai Ganesan, Oladayo A. Oyebanji, Igor Vishnepolskiy, Elise M. Didion, Alexandra Paxitzis, Maegan L. Sheehan, Eleftherios Mylonakis, Brigid M. Wilson, Alejandro B. Balazs, Philip A. Chan, Christopher L. King, Walther M. Pfeifer, Evan Dickerson, David H. Canaday, Stefan Gravenstein
Publikováno v:
medRxiv
We examined whether the second monovalent SARS-CoV-2 mRNA booster increased antibody levels and their neutralizing activity to Omicron variants in nursing home residents (NH) residents and healthcare workers (HCW). We sampled 367 NH residents and 60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4cc325763dfb08a90b42e2b0443501e
https://europepmc.org/articles/PMC9901038/
https://europepmc.org/articles/PMC9901038/
Publikováno v:
International Journal of Environmental Research and Public Health; Volume 20; Issue 1; Pages: 646
(1) Background: Respiratory co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other viruses are common, but data on clinical outcomes and laboratory biomarkers indicative of disease severity are limited. We aimed to
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19:A Randomized Controlled Trial
Autor:
Christina, Barkauskas, Eleftherios, Mylonakis, Garyfallia, Poulakou, Barnaby E, Young, David M, Vock, Lianne, Siegel, Nicole, Engen, Greg, Grandits, Nilima R, Mosaly, Andrew M, Vekstein, Ralph, Rogers, Fadi, Shehadeh, Matthew, Kaczynski, Evangelia K, Mylona, Konstantinos N, Syrigos, Vasiliki, Rapti, David C, Lye, Diong Shiau, Hui, Lindsay, Leither, Kirk U, Knowlton, Mamta K, Jain, Rubria, Marines-Price, Alice, Osuji, J Scott, Overcash, Ioannis, Kalomenidis, Zafeiria, Barmparessou, Michael, Waters, Karla, Zepeda, Peter, Chen, Sam, Torbati, Francis, Kiweewa, Nicholus, Sebudde, Eyad, Almasri, Alyssa, Hughes, Sanjay R, Bhagani, Alison, Rodger, Uriel, Sandkovsky, Robert L, Gottlieb, Eriobu, Nnakelu, Barbara, Trautner, Vidya, Menon, Joseph, Lutaakome, Michael, Matthay, Philip, Robinson, Konstantinos, Protopapas, Nikolaos, Koulouris, Ivan, Kimuli, Amiran, Baduashvili, Dominique L, Braun, Huldrych F, Günthard, Srikanth, Ramachandruni, Robert, Kidega, Kami, Kim, Timothy J, Hatlen, Andrew N, Phillips, Daniel D, Murray, Tomas O, Jensen, Maria L, Padilla, Evan X, Accardi, Katy, Shaw-Saliba, Robin L, Dewar, Marc, Teitelbaum, Ven, Natarajan, Sylvain, Laverdure, Helene C, Highbarger, M Tauseef, Rehman, Susan, Vogel, David, Vallée, Page, Crew, Negin, Atri, Adam J, Schechner, Sarah, Pett, Fleur, Hudson, Jonathan, Badrock, Giota, Touloumi, Samuel M, Brown, Wesley H, Self, Crystal M, North, Adit A, Ginde, Christina C, Chang, Anthony, Kelleher, Stephanie, Nagy-Agren, Shikha, Vasudeva, David, Looney, Hien H, Nguyen, Adriana, Sánchez, Amy C, Weintrob, Birgit, Grund, Shweta, Sharma, Cavan S, Reilly, Roger, Paredes, Agnieszka, Bednarska, Norman P, Gerry, Abdel G, Babiker, Victoria J, Davey, Annetine C, Gelijns, Elizabeth S, Higgs, Virginia, Kan, Gail, Matthews, B Taylor, Thompson, Philippe, Legenne, Richa, Chandra, H Clifford, Lane, James D, Neaton, Richard, Williams
Publikováno v:
ACTIV-3/TICO Study Group*, Nielsen, H, Thisted, R K, Petersen, K T & Juhl, M R 2022, ' Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial ', Annals of Internal Medicine, vol. 175, no. 9, pp. 1266-1274 . https://doi.org/10.7326/M22-1503
BACKGROUND: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. OBJECTIVE: To investigate if ensovibep, in addition to remdesivir and other standar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d142eddc0f692abd7c33d99b51bb4e
https://vbn.aau.dk/da/publications/828dfc6c-d4d0-47b8-a749-9cc4901459a8
https://vbn.aau.dk/da/publications/828dfc6c-d4d0-47b8-a749-9cc4901459a8
Autor:
Fadi, Shehadeh, Gregorio, Benitez, Evangelia K, Mylona, Quynh Lam, Tran, Maria, Tsikala-Vafea, Eleftheria, Atalla, Matthew, Kaczynski, Eleftherios, Mylonakis
Publikováno v:
The Journal of infectious diseases.
Thymosin-α-1 (Tα1) may be a treatment option for COVID-19, but efficacy and safety data remain limited.Prospective, open-label, randomized trial assessing preliminary efficacy and safety of thymalfasin (synthetic form of Tα1), compared with standa
Autor:
Gregorio Benitez, Fadi Shehadeh, Evangelia K. Mylona, Quynh-Lam Tran, Maria Tsikala-Vafea, Eleftheria Atalla, Matthew Kaczynski, Eleftherios Mylonakis
Publikováno v:
International Immunopharmacology. 116:109831
Publikováno v:
Annals of Internal Medicine. 175:JC10